Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (August 2006)
30 slides from Pyc Therapeutics's investor presentation, Aug 31, 2006
Slide 1: Phylogica Investor Presentation
PHYLOGICA AUGUS) DR STEWART WASHER CHIEF EXECUTIVE OFFICER
Slide 2: Corporate Overview
Corporate Overview ga Major Shareholders (Top 3 = 50%) mgsand. ‘Biotech Capital Ltd: 26.9% ' we Institute for Child Health Research: 19.0% Dr Paul Watt (inventor)... 41% s at Jul06) 108.6 (63.5 in escrow) : 14.5m options + ESOP Hutiiens 09, Menta 28 Feb tar PHYLOGICA. | ie
Slide 3: Recent Events
ent Events _ uropean patents granted on core technology . I Trials - trials positive - PHYLOGICA.
Slide 4: Why Invest in PYC?
Why Invest in PYC ? eople, Technology and Market — PHYLOGICA
Slide 5: News Flow
News Flow eals ‘and revenue. flow next 12 months to significantly re-rate stock 365) a and burns preclinical data and deals d'good cash position PHYLOGICA
Slide 6: Business Model
Business Model partner early, partner well > Early Revenue, Capital Growth, Trade Sale Potential PHYLOGICA
Slide 7: Development Portfolio
Development Portfolio PHYLOGICA. AO ip yon _
Slide 8: Drug Pipeline
Drug Pipeline © muah ENT oS Collaborators Maton 2 Lee + -J&J Research PARIS . oe panne ff © Garvan Institute 7 Institute ~@ Mimotopes ©. ~~ Axela Biosensors © Dual Systems A\ -@ Uni_of Melbourne RUA po Massachusetts G tiple diseases ¢ are. based on inflammation: PHYLOGICA
Slide 9: The Perfect Drug
The Perfect Drug _ the. sease no side effects, cost effective,
Slide 10: Phylomer Drugs
Phylomer® Drugs ecurring protein parts that ylomer® drugs can be selected that specificall y bind d block disease causing proteins
Slide 11: Evolution of Antibody Drugs
n of Antibody Drugs Traditional antibody drugs — CAT, Morphosis, Dyax ntibodies — Domantis (Peptech), ‘Ablynx Phylomer® drugs (parts of proteins) = Phylogica a PHYLOGICA.
Slide 12: Commercial Proposition
Commercial Proposition eyond antibodies - | (Patient Friendly) alty stack (More Profits) ylomers® also can be used for disease targets z de cells (Antibodies cannot penetrate cells) PHYLOGICA. te
Slide 13: Stroke: cells surrounding the initial event die
oke he cells surrounding the.initial event die ays. : Impairment of function (penumbra) ae Structural lesion oe Days &weeks _ PHYLOGICA.
Slide 14: Stroke project status and milestones
of project drug. PYC36S completely prevented 7 ‘Milestones 36S.and other stroke leads are being validated in 2d animal models of stroke (NMRI and UTAS).-~ ees aré réviewing the data PHYLOGICA
Slide 15: Burns are the third leading cause of accidental death
ies are the third leading cause of accidental iS] = PHYLOGICA. ] ee
Slide 16: Burns
Burns | ‘of project: a nd commercial agreements executed Bis being progressed i in preclinical trials at 1b Foundation — oe bs PHYLOGICA
Slide 17: Board and Management
Board and Management blend of experience and expertise Mr Joachim (Aki) v von Roy ‘Chairman +P oven ack record i in building profitable biotech companies 7 Dr Paul Watt — Vice President Technology Development + Over 7-years commercial biotechnology experience ral apeiliitments at Oxford and Harvard
Slide 18: Board and Management
Board and Management — Blend of experience and expertise D Greg Pullen - Vice President Corporate Development er. 20 years experience in. athe pharmaceutical and or Business Development rs commercial biotechnology and molecular: logy experience «Complementary knowledge and expertise in n business ma
Slide 19: Founding Partnerships
Founding Partnerships
Slide 20: Global Biotech Comparators
Global Biotech Comparators ealising value: ‘several biotechnology companies in the proven biological drug discovery ith Domantis i in earlier stage development PHYLOGICA
Slide 21: Summary
Summary ISCOVETY technology (rare/high value) mers® with major advantages over other drugs ality: portfolio to treat unmet market needs: 3S), Burns treatment (PYC35B) and RA new drugs can be developed from the national positioning) — Jeals with J&J Research, Opsona and more coming C.is favourably pr
Slide 22: Beyond Antibodies
— “Beyond Antibodies ief Executive Officer _ PHYLOGICA
Slide 23: Supplementary Slides
Slide 24: Rheumatoid Arthritis
Rheumatoid Arthritis _ arket of US$7 billion — toi Arthritis (RA) is a chronic autoimmune round 1% of the po atments represent significant, eyond current therapies; “ Reduced cost of goods «= No intellectual property royalty. stack Alternative delivery. Potential PHYLOGICA.
Slide 25: Rheumatoid Arthritis
Rheumatoid Arthritis j recently received A$2.3 million of funding from it grant for this project ee fargets a are being screened for Phylomer® blockers : it will be tested in cell assays . | be tested at the University of Melboume i in animal RA disease.models. PHYLOGICA
Slide 26: Treated wounds close faster than untreated wounds
Treated wounds close faster than untreated wounds Distance not epithelialised fmm Re-epithelialisation of 10mm full thickness wound 12 8 \ —— Control 6 _ \ ra ~~ PYC35B 4 Day post-injury nd:.A cm. diameter. burn injury.-Treated wounds (orange e*faster than untreated wounds (blue. circles) —-by day 1
Slide 27: Treated wounds undergo markedly less cell death
Treated wounds undergo markedly less cell death surrounding the site of Injury ing, OF eated! and control wounds © Wound edge 500 m 1500 m increasing distance from wound edge PHYLOGICA
Slide 28: Treated wounds have less cell death surrounding the wound edge
Treated wounds have less cell death surrounding the wound edge post-injury Intensity of TUNEL staining in Cells adjacent to Burn Injury &@ PYC35B Untreated Relative Intensity > Distance from Burn end: Relative . cell: death -at the wound. edge. Untreated ue) show. more cell death at:the edge of the
Slide 29: Burns
_Burns e burn. ounds of treated | mice 2 showed; dly less inflammation PHYLOGICA
Slide 30: Phylogica
PHYLOGICA AUGUS) DR STEWART WASHER CHIEF EXECUTIVE OFFICER